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Most people infected with HIV live in Africa where access to health care is limited. 
Antiretroviral Therapy (ART) is not yet the standard of care for those with advanced 
disease. Recent studies of the outcomes of HI VIA IDS progranunes are mostly focused on 
evaluating ART progranunes in terms of the cost-effectiveness and feasibility of 
providing ART in resource-limited settings. The integrated HIV/AIDS progranune in 
Khayelitsha (where patients on ART and not on ART are followed) provides a unique 
opportunity to explore overall progranune outcomes irrespective of subsequent access to 
antiretrovirals. 
Aim 
The aim was to describe the profile a nd clinical 0 utcomes 0 fall persons a ttending an 
HIV -service in a resource-limited setting, in Khayelitsha, Cape Town. 
Design 
A cohort of persons infected with HIV in Khayelitsha was followed up prospectively 
from the time of enrolment in 2002 until 30th of June, 2004. The existing database of 
patients was validated using records of opportunistic infections, laboratory markers such 
as CD4 count, and other outcomes such as death or loss to follow up. 
Results 
A total of 534 HIV -infected patients were studied. The median age was 31 years and 392 
were women (73%). The baseline demographic and clinical characteristics revealed the 











women (60.0kg) and men (58.8kg), (p=0.114); there was a significant difference in the 
median baseline CD4 count between women (241 cells/~l) and men (154 cells/~l), 
(p=0.015); 15.4% of all patients had an AIDS-defining illness (WHO HIV clinical stage 
IV) and 30.9% h ad a history 0 f p lior tuberculosis (TB) at the time 0 f enrolment. The 
median CD4 cell count at first visit was highest for patients referred from the Programme 
for the Prevention of Mother to Child Transmission (394 cel1/~I). 
Approximately 50% of the cohort were lost to follow-up and 21 % started ARV therapy 
during the peliod studied. The L TF group was analyzed and the median baseline CD4 
cell count was 261 cell/~l compared to 185 .5 cell/~l for those not LTF (p=0.039). The 
median duration of care was 16.2 months for those not receiving ART and there was no 
significant difference for different CD4 count categories (p=0.234). Age in years, male 
sex and previous history ofTB were significantly associated with LTF (p-value < 0.001). 
The cumulative estimate of survival was 90% in the first year and 87% at 18th months for 
those not yet on ART. There was no significant difference when comparing different 
categories ofCD4 count (p=0.87) in the survival estimate. 
Seventy eight percent of the cohort remained free of TB by the end of the second year. 
Restlicting the analysis to those not receiving ART and with CD4 count <200 cells/~l, 











One hundred and fourteen (21.3%) of the total cohort started ART during enrolment. 
Fifty percent of those with a CD4 count <50 cells/ ).!I started ART by the second year and 
45% of those with a CD4 count between 50 and 200 cells/).!I (product-limit estimate) . The 
product-limit estimate of being lost to follow-up after starting ART was 3% by the first 
year. The product-limit estimate of survival was 87% at the lih month with significant 
improvement in both CD4 count and viral load. 
Conclusion 
The Khayelitsha HIV programme has been extensively reported in terms of ART 
outcomes. This is the first attempt to review overall clinical outcomes for all adults 
enrolled in care. 
The rate of loss to follow-up is higher than expected and severely comprises the ability of 
the programme to report on non-ART outcomes. An examination of sources of referral 
and CD4 counts does however go some way to explaining the loss to follow-up. 
The time to starting ART was long and could have been shorter. The outcomes for those 
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1.1 LITERATURE REVIEW 
1.1.1 AIDS and the immune system 
The immune system is a complex network of cells and organs t hat works together to 
defend the body against foreign organisms. This system is highly developed and produces 
millions of different antibodies and cells, which help to target specific organisms 
effectively. In the early 1980's people in the United States (particularly homosexual men 
and haemophiliacs) acquired infections in alarming numbers, rarely seen in healthy 
adults. It was soon recognised that infection with a virus, Human Immunodeficiency 
Virus (HIV), resulted in the depletion of an important component of the immune system, 
the C D4+ T cells. T he loss 0 f these c ells I eft t he body vulnerable to infections that 
would normally be controlled by a healthy immune system (Stine 1993). 
AIDS was described as a collection of symptoms that make up a recognisable pattern and 
have a similar cause - the acquisition of infection with HIV, transmitted through the 
exchange of bodily fluids from someone infected with HIV. The bodily fluids that 
contain sufficient amounts of HIV to be able to transmit infection are blood, semen, 
vaginal secretions and breast milk (Stine 1993). 
The impact of HIV on the immune system is the important feature of AIDS. HIV itself 
does not directly kill people but it rather weakens the immune system and people infected 
with HIV are vulnerable to diseases that they would normally resist. These diseases are 










system to spread and cause disease. The range of opportunistic infections differs 
depending on the prevalent infections in an area. HIV not only makes both existing 
diseases more common and more severe (e.g. tuberculosis) but also makes rare diseases 
more common (e.g.,pneumocystis carinii pneumonia, Kaposi's sarcoma). 
1.1.2 Epidemiology and burden of HIV 
1.1.2.1 The global HIVIAIDS epidemic 
HN I AIDS is the leading cause of mortality among adults aged 15 to 59 years in the 
developing world and it is in the top 10 leading causes of all deaths reported by the 
World Health Organization in 2003 (World Health Organization 2003). Ischemic heart 
disease (IHD) and tuberculosis (TB) ranked second and third, respectively, for thjs age 
group. For adults of age 60 years and older, IHD, cerebrovascular disease (CVD), TB and 
colon and rectum cancers are the main causes of death (World Health Organization 
2003). 
It is estimated that 40 million people were living with HIV/AIDS, 5 million new 
infections with HIV and 3 million deaths from HIV in 2003 (UNAIDS 2004). Sub-
Saharan Africa has the highest number of adults and children living with HIV I AIDS 











Figure 1: Adults and children estimated to be living with HIV/AIDS as of end 2003 i . 
In Sub-Saharan Africa, the estimated number of adults and children living with 
HIV/AIDS at the end of 2003 was 28.2 million, (World Health Organization 2004). 
However, not all African countries exhibit the same patterns of HIV prevalence and there 
are very large differences in Sub-Saharan African countries (samoah-Odei, Garcia 
Calleja, & Boerma 2004). 
1.1.2.2 HIVIAIDS in South Africa 
The estimated number of adults and children living with HIV I AIDS in South Africa by 
the end of 2003 was 5.3 million, of which adults aged 15 - 49 years comprised 5.1 
million and children aged 15 years and younger numbered 230 000. The number of 
women in the age group 15 to 49 years living with HIV I AIDS was 2.9 million (UNAIDS 
2003). 











In South Africa, as many other countries, national sentinel HIV sero-prevalence surveys 
of antenatal clinic (ANC) attendees have been conducted since 1990. HIV prevalence 
among pregnant women in South Africa has increased since 1990. In 2003, the 
prevalence was 27.9% compared to 26.5% in 2002. This increasing pattern is evident 
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Figure 2: prevalence of HN among antenatal care attendees in South Africa, 1990 - 2003. 
These findings show that the HIV prevalence rates remain high and that between 
provinces variations are observed. A prevalence rate of 37.5% was observed for 
KwaZulu-Natal followed by Mpumalanga (32.6%), Free State (30.1 %), Gauteng (29.6%) 
and Eastern Cape (27.1 %). The other provinces showed prevalence rates below 20% with 
the Western Cape having the lowest prevalence (13.1 %). HIV prevalence by age group 
showed that the age group 25 to 29 has the highest rate (35.4%) and that the lowest 
prevalence rate (15.8%) was recorded among teenagers (and particularly women under 20 











While the antenatal surveys have been useful III determining trends overtime, they are 
less reliable for generating population-level estimates (Fylkesnes et al. 1998;Kigadye et 
al. 1993) as only pregnant women who use public sector health-care facilities were 
included. This can produce different types of bias because it excludes not only women 
attending private health-care institutions, but also women who are not pregnant and all 
men and children. One of the latest studies using the general South African popUlation to 
determine HIV prevalence was done by Connolly (Connolly et al. 2004) . It was one of 
few national community-based HIV surveys conducted in South Africa. A sample of 
persons over 2 years of age from both sexes and of all racial groups was included in the 
study using pre-designed geographical maps of households around South Africa. HIV 
prevalence in the general population was estimated to be 11.4 % (12.8% in females and 
9.5% in males) and varied significantly by province from 6.6% in the Eastern Cape to 
14.9% in the Free State. The prevalence in pregnant women was 24% which is similar to 
estimates from t he I atest antenatal surveys (Department 0 f Health 2 002;Department 0 f 
Health 2003a). 
1.1.2.3 Impact of HIVIAIDS in South Africa 
A study by (Bradshaw et al. 2003) has reported on the estimated burden ofHIV/AIDS. It 
asserted that HIVI AIDS accounted for 30% of deaths in 2002 and the proportion of HIV-
related deaths in women was higher than deaths due to injury in men. Young adults of 
both sexes were most affected. In terms of years of life lost (YLL), 38% of YLL was due 











1.1.2.4 HIVIAIDS in Khayelitsha 
1.1.2.4.1 HIVIAIDS epidemic i" Khayelitsha 
One of the most affected areas at national and provincial level is Khayelitsha in the 
Western Cape Province. Khayelitsha is a poor township 30 kilometers from the centre of 
Cape Town, South Africa, (figure 3). Khayelitsha is one of the fastest growing townships 
in Africa and has 500,000 inhabitants of whom 50% are unemployed and more than 70% 
live in infonnal housin~ (figure 4). 
At the beginning of 1999, the antenatal prevalence of HIV was 15.0%, increasing to 
19.3% in 2000, 24.7% in 2002 and to 27.2% in 2003 (Department of Health 
2003b;M6decins Sans Frontieres (MSF) & Infectious Disease Epidemiology Unit 2004). 
These rates reflect the national prevalence rather than those of the Western Cape as 
shown in Table 1. 
Table 1: "IV prevalence in South Africa, Western Cape Province and Khayelitsha district i 
Year National Western CaEe KhaJ:'elitsha 
2000 24.5% 8.7% 19.3% 
2001 24 .8% 8.6 23 .2% 
2002 26.5% 12.4% 24 .7% 
2003 27.9% 13.1% 27.2% 
Despite the fact that the Western Cape Province had the lowest antenatal HIV prevalence 
rate nationally, homicide and HIV/AIDS are amongst the top ten causes of premature 
deaths in Cape Town and sub-districts in 2001 (Groenewald et al. 2003). In Khayelitsha, 
premature deaths due to homicide accounted for 22.3% followed by HIV/AIDS (17.0%) 
and TB (13.3%). 











1.1.2.4.2 Brief description of Khayelitsha and ARV programme 
In January 1999, the Health Department of the Provincial Administration of the Western 
Cape (PA WC) introduced a programme for the Prevention of Mother to Child 
Transmission (PMTCT). This resulted in the identification ofmany women who were 
infected with HIV. In response, PAWC concluded an agreement with the international 
medical NGO, M6decins Sans Frontieres (MSF) in April 2000, to open clinics for 
patients with HIV -related problems within three community health centers in 
Khayelitsha. Three clinics at different sites started providing comprehensive care for 
persons infected with HIV. The clinics provide appropriate counselling, support, 
prophylaxis, treatment, screening and refelTal for conditions related to HIV / AIDS. They 
aim to provide comprehensive care for HIV infected patients in the primary health care 
setting. 
MSF started providing in Highly Active Antiretroviral Therapy (HAART) in May 2001. 
The aim of this pilot project was to test the effectiveness, feasibility, acceptability and 
cost-effectiveness of providing HAART in a primary health setting. MSF requested the 
technical assistance of the School of Public Health and Family Medicine at the University 













Figure 3: Diagram illustrates the location of Khayelitsha ; G. Map of Africa, b. Map of South Africa, c. 
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1.1.3 Clinical epidemiology of HIV I AIDS and HIV services 
1.1.3.1 Survival, causes of death and incidence of opportunistic infections (OJ's) 
Studies of clinical outcomes of routine dedicated HIV services in developing countries 
are few. A study by (Okongo et al. 1998) explored the causes of death in a rural 
population in Uganda. It included all deaths rather than a biased sample of autopsy data 
only. In addition, all clinic staffs were blind to the HIV serostatus of the participants. The 
causes of death in HIV-infected persons included wasting syndrome (31 %), chronic 
diarrhoea (22%), cryptococcal meningitis (13%), and chest infections (non-TB) (11%). 
Eighty seven percent of deaths were in patients classified in WHO stage IV (AIDS). 
The epidemiology of opportunistic infections vanes In developed and developing 
countries . In a retrospective study done in London (Petruckevitch et al. 1998), the initial 
AIDS defining conditions in 627 patients attending HIV/AIDS units were Pneumocystis 
carinii pneumonia (25%), tuberculosis (16%), Kaposi's sarcoma (15%), oesophageal 
candidiasis (10%) and other conditions (12%). Most persons with AIDS in developed 
countries do not die from infectious diseases but rather from lymphomas (Franceschi, 
Dal, & La 1999). On the other hand, in developing countries AIDS defining conditions 
have a significant impact on the prognosis of HIV infection. In one study conducted to 
define the natural history and disease progression of HIV infection in Haiti, a developing 
country, (Deschamps et al. 2000), the AIDS defining conditions that had the highest 
impact on survival were tuberculosis, wasting syndrome, cryptospordiasis, cyclosporiasis, 











HIV has different impacts on the progression and mortality and morbidity of many other 
diseases. For example, patients with haemophilia have shown that the incidence of end-
stage liver disease and hepatocellular carcinoma are increased in HIVlhepatitis C virus 
co-infected individuals compared with non-infected individuals (Eyster et al. 1993;Telfer 
et al. 1994). Also, several histological epidemiological studies have suggested that 
hepatic fibrosis, the main cause of morbidity and mortality from hepatitis C virus 
infection(HCV), is increased two-fold in HIV/HCV co-infected individuals (Benhamou et 
al. 1999;Puoti et al. 2001). 
Little is known about the progression and natural history of HIV in developing resource-
limited countries. A number of studies have been conducted in developed and developing 
countries to determine the survival after seroconversion and after AIDS. In a population 
based cohort study (Morgan et al. 2002), comparing the differences in survival between a 
poor setting country like rural Uganda in Africa with industrialized countries, the results 
showed that the median survival from seroconversion was 9.8 years in Uganda compared 
to a survival time of around 10 years in industrialized countries. The study concludes that 
although the median survival after infection was similar, the time from an AIDS defining 
illness to death was shorter (9 .2 months). However, survival with AIDS tends to be 
shorter in Africa (Grant, Djomand, & De Cock 1997). 
Studies in two cohorts of HIV-l-infected adults, mostly women, in Uganda (Morgan et 
al. 1997) and Cote d'Ivoire(Salamon et al. 2002), showed that the chance of remaining 











services and the existing health status of most African populations contribute to the rapid 
development of AIDS and there is no difference in the progression of HIV infection by 
sex (Danel et al. 2002). 
1.1.3.2 CD4 changes and HIV progression 
The progression and natural history of HIV infection are known to be more rapid in 
Africa and Asia than in other developed countries (Kitayapom e t al. 1996;Nunn et al. 
1997). The explanations for this rapid progression includes lack of access to health care, 
co-infection with other pathogens and malnutrition (Camp et al. 1998;Del Arno et al. 
1998;Lucas, Odida, & Wabinga 1991). CD4 count and level of HIV RNA (viral load) are 
known markers and predictive of clinical progression to AIDS in developing countries 
(Anastos et al. 1999;Vlahov et al. 1998). The progression of these markers is not 
consistent. In one study in India (a developing country) (Mehendale et al. 2002) , the 
annual increase in HIV viral load was 8274 RNA copies/ml/year and the annual decline 
in CD4 cell count was 120 cells/year. The study reported that the median increase in viral 
load in Indian seroconvertors was greater than that reported in untreated HIV 
seroconvertors in the United States. Hence, the study suggested, the rapid increase in 
viral load within the first 2 years may change considerations when applying treatment 
guidelines for ART and prophylaxis. The progression may change when ARV therapy is 
provided in resource-limited settings, with reported improvements from baseline levels 
of CD4 counts. In one study done in South Africa (Coetzee et al. 2004), the reported CD4 
count progression after 6 months of ART, compared to pre-treatment levels, increased by 











count compared to baseline was 288 cells/ill and the median absolute CD4 count at this 
duration on treatment was 323 cells/ Ill. This study concluded that ART could be 
provided in resource-limited settings with good patient retention and clinical outcomes. 
1.1.3.3 HIVand TB 
The advent of the HIV epidemic has increased the burden of TB significantly and TB is 
the I eading cause of mortality in H IV infected persons. Tuberculosis disease increases 
mortality in HIV -infected patients (Leroy et al. 1997; Whalen et al. 1995) and patients co-
infected with HIV and tuberculosis have high rates of reactivation of latent tuberculosis 
infection (L TBI) (Moss et al. 2000;Selwyn et al. 1 989). In some countries, more than 
70% of the TB patients are HIV -infected (Raviglione et al. 1997) and this has had a 
dramatic effect on the T B epidemic inS ub-Saharan A frica a nd requires effective HIV 
prevention as a priority for TB programmes (Bleed, Dye, & Raviglione 2000). 
HIV is the strongest factor capable of promoting progression of Mycobacterium 
tuberculosis (MTB) infection to active tuberculosis (Rieder et al. 1989) both in people 
with recently acquired and with latent MTB infections (Maher, Floyd, & Raviglione 
2002). The lifetime risk for active TB in an HIV -negative person is 5 to 10% while the 
annual risk in HIV-infected persons is 5 to 15% (von Reyn 1999). 
Research shows that even in areas where there is a good TB control program, when the 
sero-prevalence of HIV is greater than 20%, the annual percentage increase in TB will be 











associated with decreased survival. TB specific mortality is four-fold higher among HIV-
infected patients than amongst the uninfected (17.8 and 4.4 deaths per 100 per year for 
HIV -infected and uninfected patients respectively) (Connolly et aI. 1999). In addition the 
TB epidemic in persons infected with HIV increases the infectious pool and the risk of 
TB transmission in the corrununity, whether or not HIV-infected (Maher, Floyd, & 
Raviglione 2002). 
In resource-poor countries in Sub-Saharan Africa, 32% of patients with TB are HIV-
infected. The prevalence of both HIV and TB patients is above 10%. The burden of co-
infection is concentrated in Sub-Saharan African countries where the two infections 
highly prevalent (Girardi et aI. 2000b). The estimated tuberculosis incidence rate was 
191/1 00 000 in 1990 compared to 257 in 1997 in Africa. In industrialized countries i the 
incidence rate was 23 per 100000 in 1990 and it had dropped to 16 by 1997. 
A study was conducted of the changes in biological markers of HIV infection before and 
after the development of TB disease in a cohort of HIV -positive Ethiopians (Wolday et 
al. 2003). In this longitudinal study 804 adult factory workers (95 HIV-positive, 709 
HIV-negative), were followed for a median of 3.8 years at 6 months intervals. The HIV-
infected participants who developed TB disease had low CD4 counts (median 20Icell/lll, 
range 45 - 419), and high viral load (median 4.97 log copies/mI, range 3.70 - 5.58). 
However, there is a higher incidence of TB in all stages of HIV. In one study, 25% of 
patients with TB had a CD4 cell count above 500 cell/Ill at time of diagnosis. The same 











study shows that the incidence of TB among HIV -infected participants was higher than 
HIV-negative participants (45 .1 versus 6.8 per 1000 persons years). 
1.1.3.4 TB and Antiretroviral Therapy (ART) 
In the era of ART the clinical features of AIDS defining conditions may change in 
addition to the incidence of opportunistic infections and mortality. ART and to a far less 
extent other prophylactic drugs will change the natural history and progression ofHIV. 
In developing countries, TB occurs more frequently than in industrialized countries and it 
accounts for more than one third of mortality among HIV -infected patients in Sub-
Saharan Africa (De Cock et al. 1992;Greenberg et al. 1995). Lack of resources in Africa 
has limited access to ART, but studies on effectiveness of such treatment shows 
significant impact 0 fA RT on T B. Ina cohort study (Badri, Wilson, & Wood 2002), 
conducted in Cape Town (South Africa), the investigators compared the risk of 
tuberculosis in two cohorts, one receiving HAART and the other not. The HAART 
cohort accrued from 12 clinical trials carried out between 1995 and 2001 in Cape Town. 
The n on-HAART cohort consisted 0 f patients who attended clinics between 1 992 and 
2000 in Cape Town. The baseline clinical characteristics did not include viral load, as this 
was not always available. Other predictors including CD4, WHO clinical stage, and 
socioeconomic status where included in the analysis. The results of the study showed a 
significant association between HAART and lower incidence of tuberculosis (2.4 per 100 
patient-years in HAART cohort versus. 9.7 per 100 patient-years in non-HAART). The 
results also showed that the greatest number of TB cases averted by HAART was in 











cellll·d. The study showed an 81 % (95% CI 62-91) reduction in the risk of TB associated 
with use of HAART. This is similar to studies in the US (Jones et al. 2000) and Italy 
(Girardi et al. 2000a). 
1.1.3.5 HIV and Antiretroviral Therapy (ART) 
The benefits of ART in reducing mortality have also been shown in resource-poor 
settings. A study in Khayelitsha (Coetzee, Hildebrand, Boulle, & et al 2004), showed that 
cumulative survival on antiretroviral treatment was 86.3% at 24 months, similar to other 
studies in African settings (Laurent et al. 2002;Weidle et al. 2002). Survival without ART 
reported in another study in Cape Town for those with CD4 count less than 50 cellS/ill 
was less than 12 months (Post, Wood, & Maartens 1996). The survival outcomes were 
similar to that reported in Canada and USA (Chan et al. 2002) for patients with very low 
CD4 cell counts at the time of initiation of ART. 
1.2 Motivation of the study 
There are few studies that deal with outcomes of populations seeking routine HIV care in 
the era of ART in Africa. 
1.3 Aim of the study 
The aim of the study was to describe the profile and clinical outcomes of HIV -infected 












1.2.1 Specific objectives 
1. To describe the profile of patients enrolled at the HIV service including: 
• Demographic variables 
• Stage of disease 
• Source of referral 
2. To determine the clinical outcomes of HIV -infected patients who are not on ART 
therapy in order to determine 
• The proportion of patients who are placed on ART, 
• The proportion of patients who died. 
• The proportion of patients lost to follow up. 
3. To determine the incidence of tuberculosis infections amongst HIV-infected 
patients who are not on ART. 
4. To examine risk factors, such as demographic variables, CD4 cell count, HIV 
stage 0 rap revious history 0 f T B, associated with the incidence 0 f T B among 
HIV-infected patients who are not on ART. 












2.1 SUBJECTS AND METHODS 
2.1.1 Definition of terms 
HIV: Refers to HIV-l unless otherwise indicated. 
History of TB: Any episode of TB before emollment at the service. 
HIV clinical stage: Refers to the HIV clinical staging proposed by World Health 
Organization (World Health Organization 1990) 
2.1.2 Study design 
The study design used was a follow up of a cohort of HN -infected patients using 
prospectively collected data that was validated. 
2.1.3 Study population and sampling 
2.1.3.1 Study population 
The study population was all HIV -infected patients who emolled at Site B HN service in 
Khayelitsha during 2002. 
2.1.3.2 Study setting 
The subjects were patients from Khayelitsha Site B HIV service. Site B-HIV clinic is 
one of three clinics providing free counselling, treatment and follow up of HN -infected 
persons. This study was part of a larger project currently ongoing in Khayelitsha. 
2.1.3.3 Sampling 
All adult patients attending the service at Site B for the first time from the 1 st January 











2.1.3.4 Sample size 
As there are many outcomes, for the purposes of sample SIze, the following three 
calculations were performed with a significance level of 0.95 and a power of 0.90. 
• Comparing loss to follow-up between men and women, asswning 30% 
and 15% loss to follow-up respectively, the calculated sample size required 
was 396 (132 men and 234 women) 
• Comparing the proportion of patients with a new tuberculosis diagnosis 
in the first year of follow-up in patients enrolling in clinical stage II with 
patients enrolling in clinical stage IV and assuming equal numbers in each 
stage the calculated sample size was 348. 
• Determining the proportion of patients enrolling In care In stage IV. Using a 
precision of 0.1 - the calculated sample size is 233 
The total number of adults enrolled inc are during 2002 a t the Site B clinic was 534, 
suggesting that the above sample sizes were achieved with the proposed sampling 
strategy. 
2.1.4 Data collection 
All information was extracted from the electronic database. In order to verify and validate 
data, clinical records were used. The following information were collected; age and 











infections and AIDS defining illnesses, prophylaxis and treatments, and CD4 cell counts 
and HIV RNA levels, sputum smears and culture results for TB and infonnation from 
chest radiographs. 
(Appendix A includes Data Record Sheet with the infonnation require to be validated) 
2.1.5 Pilot study 
This study was piloted In order to ensure that the data were correctly defined and 
captured. About 30 records from database were verified with the clinical records at Site B 
clinic. Difficulties in extracting and entering data were identified and corrected. 
2.1.6 Data management and statistical analysis 
The data were checked for errors and corrected before and after entry into the database. 
Clinical data had already been entered once into a database, and this process was 
validated. 
After cleaning the data, graphical explorations and listings were done to check for errors 
and to elicit patterns and relationships. For purposes of this study and its specific 
objectives, the analysis was divided into two sections, descriptive and analytical. In the 
descriptive section, the main statistical methods used were proportions and percentages, 
cross tabulations a nd graphical displays. In addition, the t -test for two samples 0 n the 











For the analytical se ction, a range 0 f classical a nd modeling approaches were used in 
detennining outcomes including: Survival analysis and proportional hazards regression 
for the mortality and loss to follow-up outcomes as well as the time to the first event for 
TB and certain opportunistic infections. Patients were categorized into strata according to 
CD4 cell count of <50, > or = 50 and <200, and> or =200). A P value of less than 0.05 
was used in all analyses as a measure of statistical significance. Loss to follow-up was 
right-censored in this analysis. 
Analyses was performed using STA TA ™ 8.0 Statistics/Data Analysis software package 
(Copyright 1984-2003, Stat Corporation, 4905 Lakeway Drive, College Station, Texas 
77845 USA). 
2.1.7 Ethical and legal considerations 
This study was part of larger M SF/UCT research project currently being conducted in 
Khayelitsha to evaluate the HIV and ART services. Approval and consent from patients 
has been obtained for the project. 
Ethics approval for this project was obtained from the Research Ethics Conunittee of the 











All data was extracted from the database used to monitor the programme in Khayelitsha. 
The names of patients were not included. Clinical records were accessed to validate data. 
The confidentiality of these records was maintained at all times. 
2.1.8 Reporting of results 
All results will be reported to all major stakeholders, the local government and provincial 













3.1.1 Section 1: Descriptive analysis of the study 
This section includes a description of the baseline characteristics of the cohort at the time 
ofenrolment in 2002. In addition, sources ofreferral and the main outcomes are also 
presented. 
3.1.1.1 Demographic and baseline clinical characteristics of the cohort 
The main baseline characteristics are presented in table 2. 
Table 2: Baseline demographic and clinical characteristics of a cohort of HIV -infected persons 
attending an HIV clinic in Khayelitsha, 2002 
Cn=5342 
Characteristic N(%J Median (IQR) P-value 
Age( years) 
All 534 (100) 31.25 (27,1 - 36,8) 
Females 392 (73.4) 29,9 (26,3 - 35.5) 
Males 142 (26,6) 34 ,8 (29,8 - 41) 50,00 Ii 
Baseline Weight (kg) 
All 508 (95, I) 60 (52 ,5 - 71.6) 
Females 374 (70 ,0) 60 (52.4 - 70,9) 
Males 134 (25,1) 58 ,8 (52 ,7 - 66.7) 0,114ii 
Baseline C04+ T-Iymphocyte 
(celis/ill) 
Total C04+ 474 (88,8) 221,5 (76 - 394) 
C04+ < 200 222 (41.6) 70 ,5 (25 - 126) 
C04+ ~ 200 252 (47,2) 376 (287 - 529) 
C04 count by Sex 
Females 352 (89,8) 240 ,5 (80 - 432,5) 
Males 122 (85,9) 154 (55 - 289) 0,Ol5 iii 
PriorTB 
Yes 165 (30,9) 
No 369 (69, I) 
AIOS - defining illness 
(Stage IV) 82 (15.4) 
i Chi-squared Non-parametric K-sample test on the equality of medians(Chi-squared statistic is calculated with, and without a 
continuity correction) , 
ii Two-sample t test with equa I variances , 











The size of the study cohort who regjstered in 2002 was 534 sUbjects. Women comprised 
392 (73.4%) of the total cohort. The median age for women was 29.9 years and for men 
34.8 years (p:sO.OOl) with the inter-quartile range (lQR) being 26.3 to 35.5 for women 
and 29.8 to 41 for men. 
The median and IQR for baseline weight for all subjects in the cohort (first recorded 
weight irrespective of being at first visit or later on) was 60kg with IQR (52.5 - 71.6). 
The total number of subjects with their baseline weight recorded was 508 (95.1 %) and 
this did not differ significantly between women and men (p=O.l14). 
First CD4 count (first CD4 count irrespective of the first visit date) was available for 474 
patients or 88.8% of the cohort with a median of 222 cells/I .. t! and IQR (76 - 394 cellS/ill). 
The availability of the first CD4 count was slightly higher for women than for men, 352 
(89.8%) and 122 (85.9%) respectively. First C D4 count was significantly different for 
women and men (p=O.015) and the median CD4 count for women and men was 240.5 
cellS/ill (IQR, 80 - 432.5 cells/f-tl) and 154.0 cellS/ill (IQR, 55 - 289 cellS/ill) 
respectively. 
Forty-two percent of the cohort had baseline CD4 counts below 200 cellS/ill with a 
median of 70.5 and IQR of 25-126 cellS/ill for the same category. The first CD4 count 
was 2:200 cells/Jll for 252 patients (47.2% of the total cohort) with a median of 376 and 











One hundred and sixty five patients (30.9%) had a history of prior tuberculosis (TB) at 
the time of enrollment and 81 (15.4%) presented with an AIDS-defining conditions (HIV-
stage IV). 
3.1.1.2 Sources of referral 
Table 3 and figures 5 and 6 present the different sources of referral for the cohort with the 
median and IQR of the CD4 count at first visit for each source. Self-referral comprised 
20.2% of the total sources of referrals followed by mother-to-child transmission 
prevention programmes (MTCT) and Khayelitsha clinics (18.7%) each. Non-
Governmental Organizations and home-based care comprised only 1.3% of the total 
sources 0 f referral. The median C D4 count p resented a t first visit was highest for the 
MTCT group and the self-referral group, 394 cells/).d (IQR, 239-566) and 243.5 cellS/ill 
(lQR, 110-451) respectively. The individuals referred from hospitals and NGO's 
presented with the lowest CD4 counts at the first visit, the median and IQR was 73 (16 -
236) and 47 (25 - 105) cellS/ill respectively with a total of 32 subjects (6%) from 
hospitals and 7 (1.3%) from NGO's. TB clinics in Khayelitsha referred 67 (12.5%) of the 
HN -infected cohort and the median CD4 cOlmt was 110 cellS/ill (IQR, 54.5 - 259). Of 
the 48 recorded baseline CD4 counts for those referred from TB clinics, 32 (66.7%) were 











Table 3: Sources of referral and the median CD4+ count at the first visit for persons attended HIV 
clinic in Khayelitsha, 2002 
Sources of referral 







Hospitals (TertiQ/y & SecondQ/y Hospitals) 
NGO's (Non Governmental Organizations and Home-based 
care) 
Total 
3:uo:sct raerra fO' p:rs:n;aterdrg HI V-<:liric 
in Khaysils-a, :m2 
3.7% 6% 12.5% 
1.3% 6% 
• TBclinics 
D Khayelitsha clinics 
• Hospitals (Tertiary & secondary hospitals) 
12 .5% 
(n=534) 











N (%) 534 (100) 
• NGO 's (Non Governmental Organizations and Home-based care) 
• MTCT (Mother To Child Transmission programs) 
c Self referral 
• Non-Khayelitsha clinics 
[J Private clinicians 
[J Unknown 

































Sources of referral and median and IQR of CD4 count at teh flrts visit 
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Figure 6: Sources of referral with median and TQR of the first CD4 count for persons attending HIV 
clinic, Khayelitsha, 2002. 
3.1.1.3 Outcomes of the cohort 
The main outcomes of the cohort analyzed are summarized in table 4. Two hundred and 
sixty eight (50.2%) of the cohort were lost to follow-up (LTF) whereas the number still in 
care on ARVs was 114 (21.3%) and the number still in care without ARV was 108 
(20.2%). The other outcomes included transferred out, died of HIV, died of non-HIV 
causes and died of unknown reasons. 
Table 4: Outcomes for HfV-infected persons attending an HIV-clinic at Khayelltsha, 2002 
Outcome 
Loss To Follow up(LTF) 
Transferred out (no more follow up at Khayelitsha clinic) 
Died HIV (The cause of death recorded as HIV) 
Died (Non-HIV) 
Died (Unknown) 
Still in care on ARV treatment 






















There was a progression in the clinical stage during follow-up (table 5) with a higher 
proportion of patients being in stage IV and a lower proportion in stage I the last time 
recorded compared to the first. Table 6 presents the CD4 count stratified by stage at first 
visits. The median CD4 count for those in stage I was 380 cells/ill with IQR (263 - 504) 
and for HIV stage IV, 50 and IQR (19 - 128) cells/ill. The median CD4 dropped as 
patients progressed through from stage I to stage IV as shown in table 6. 
Table 5: HIV clinical stage at first and last visits of the persons attended HIV -clinic, Khayelitsha, 
2002 
(n=534) 
Stage At first visit At last visit 
N (%) N (%) 
J 90(16.9) 53 (9.9) 
II 128(24) 101 (19) 
III 182(34.1) 177 (33.1) 
TV 82 (15.4) 141 (26.4) 
Total 482 (90.4) 472 (88.3) 
Table 6: Summary statistics of CD4 count by stage at first visit of the HIV - infected cohort attending 







Summary of CD4 count by stage at first visit 










* Thirty four subjects did not included because they don't have specific stage 
3.1.1.4 Descriptions of lost to follow up (LTF) group 
Fifty percent of the cohort were lost to follow-up. This group is described to show some 











The source of referral for both LTF and others group is presented in Table 7. Self-referral 
is the highest source of referral for the L TF group while Khayelitsha clinics are the 
highest for others. Source of referral is the same for MTCT programme for both groups 
and the same when comparing for NGO's. 
Table 7: Sources of referral of L TF group and others 
Source of referral 
Self referral 





Hospitals (Tertiary & Secondary Hospitals) 
Non-Khayelitsha clinics 























The median CD4 cell count at first visit (irrespective of visit date), was 261 cellS/ill (IQR, 
93-444.5) in those LTF compared to 185.5 cells/).!l (lQR, 73 - 347) in those not LTF 
(Table 8). 
Comparing the munber of persons in the different CD4 count categories (Table 9) at first 
visit, 18% of subjects in both groups had a CD4 count under 50 cells/).!l. For those placed 
on ART, the last recorded CD4 count was less than 50 cells/).!I in 20% of those L TF as 
compared to 11.2% for those not lost to follow up. The distribution of the first and last 
CD4 count for both groups is presented in Figures 7 and 8. The distribution of the last 
CD4 cell count shows that there are more subjects in the categories <50 and > 200 
cellS/ill for those LTF. 
The median duration from first visit until loss to follow up was 2.1 months with the IQR 











significant difference when compaling the HIV staging at last visit for both groups, LTF 
and not LTF (p<0.001), (Table 8). 
Table 8: Description of the main characteristics of the lost to follow up (L TF) group compared to 
those not L TF. 
LTF group Other 
Characteristic 
(n) (n) 
mean Median (IQR) mean Median (IQR) p-value* 
First CD4 count (216) 
306.2 261.5 (93 - 444.5) 
Last CD4 count (216) 
303.1 259.5 (86-433.5) 
Duration before L TF in monthst (268) 
4.8 2.1 (0.4 · 7.1) 
Sex N(%) 
Females 191 (71.3) 
Males 77 (28 .7) 
H IV stage at first visit 
I 49(22 .5) 
II 57 (26.2) 
III 66 (303) 
IV 46 (21.1) 
HIV stage at last visit 
I 41 (19.2) 
II 53 (24 .8) 
III 64 (30) 
IV 56 (26 .8) 
• Two-sample t test with equal variances(L TF group and others group). 


















Table 9: Percentage of lost to follow up (L TF) and other groups in each CD4* count category at first 
and last CD4 test. 
Categories of first CD4 count p-valuet 
Group <50 <200 <500 <1000 > 1000 
L TF group(n=215) 18.6% 22.8% 40.0% 16.3% 2.3% 
Other groups(n=257) 17.9% 33.9% 36.58% 10. 1% 1.5% 0.039 
Categories of last CD4 count 
Group <50 <200 <500 <1000 > 1000 
L TF group(n=215) 19.5% 21.7% 41.4% 14.9% 2.33% 
Other groups(n=258) 11.2% 28.7% 46.1% 12.0% 1.9% 
0.504 
* CD4 count (cells/Ill) 
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Figure 7: Distribution of first CD4 count for L TF group and others in the cohort 
Distribution of last CD4 count for L TF group and others 
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Figure 8: Distribution of last CD4 count for L TF group and others in the cohort. 
The median number of visits was 3 (lQR 2-5) for those lost to follow-up compared to a 





















• Two-sample ttest with equal variances 
p-value· 
0.000 
Distribution of number of visits for L TF group and others. 
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Figure 9: Distribution of number of visits for L TF group and others . 
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3.1.2 Section II: Survival analysis for the cohort excluding person-time on ARV 
therapy 
In this section, time to L TF, time to death from HIV and time to start ART for all patients 
(excluding person time when on ART), are analyzed. 
3.1.2.1 Time to LTF in the cohort (non-ARV) 
About 50% of the cohort was L TF at the time of the analysis of this data. The time to 











of remaining in care of 16.2 months and 74% (95% CI 70 - 77%) of the cohort remained 
in care for at least 2 months before LTF (Figure 10). 
Time to L TF (non ARV) 
8 
d 
o 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 
Duration (rronths) 
Persons remaining 391 311 237 190 163 106 54 10 
LTF 133 19 13 13 
Percenlage remaining 74.8 63.7 565 50.9 48.9 48.2 44.5 41 
95% confidence interval 70 - 78 3 59.4 - 67.6 52-607 463 - 55.3 " .2- 53.3 41.5 - SO.1 39.6 - 49.3 35.0 - 46.9 
Figure 10: Time to L TF for non-ARV persons in the cohort. 
When comparing for different CD4 count categories the product limit estimate of time to 
L TF showed that those with CD4 counts <50 cells/~I were at higher risk of LTF, 
although this wasn't significant (p=0.234)' and there was not a significant trend in the 
survivor functions for these categories (p=0.37yi, (Figure 11). 
I Log-rank test for equality of survivor functions. 











When comparing the time to LTF by source of referral (TB clinics versus other sources 
of referral), there was a significant difference (p=O.036Y . Persons referred from TB 
clinics were more likely to remain in care than those referred from other sources, (Figure 
12). 
There was an significant association between male sex, age and previous history of TB 
and LTF. Table 11 presents hazard ratios and p-values for these variables included in the 
final Cox regression model. 
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Figure 11: Time to LTF in (non ARV group) by baseline CD4 count categories. 
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Figure 12: Time to LTF in (non-ARV group) by source of referral. 
Table 11: Baseline characteristics associated with L TF in non-ARV group in the cohort 
Characteristic* Hazard Ratio (HR) p-value 95%CI 
Age in years 0.97 0.000 0.96 - 0.98 
Male sex 1.37 0.008 1.1 - 1.8 
Previous history ofTB 0.64 0.031 0.48 - 0.85 
• All baseline characteristics included in Cox regression model are categorical variables except for age (continuous). 
Increase in age by one year reduces the risk of L TF by almost 3% (p<O.OO 1) and being 
male increases the risk of L TF by 37% (p=0.008). TB disease before enrolment in HIV 
care reduced the hazards ratio (p=0.03J). 
3.1.2.2 Time to Death of HIV in the cohort (non-ARV person time) 
The survival estimate at one year was about 90% and after 18 months. There was no 











test for trend p=O.89)i, (Figure 14). The survival estimates were similar for all patients 
with stratified by first CD cell count after 2 months (98%, 99%, and 97%) and after 2 
years (89%, 83%, and 88%) duration (Figure 5). 
Time to detah of HIV (non ARV) 
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Figure 13: Time to death from HIV in the cohOlt (non ARV) . 
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Figure 14: Survival estimates in the non-ARV by different CD4 levels. 











When analyzing the association between baseline characteristics and outcome "Time to 
death", only a previous history ofTB was significant (p=0.028). 
3.1.2.3 Time to start ART in the cohort 
The duration of time before starting ART was analyzed (Figure 15). Approximately 80% 
(95% CI, 75.8 - 84.8%) of the cohort remained without ART at one year and 60% (95% 
CI 52 - 65.7%) by the second year. 
Time to start ARV 
o 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 
[)jration (rronths) 
Figure 15: Time to start ARV in the cohort. 
The time from enrolment to starting ART was a minimum of 4 months. Three-quarters of 
those with an initial CD4 count < 50 cells/I .. d and who remained in care, had started ART 
by one year, and all of them had started ART by two years. Three-quarters of those who 
initially enrolled in care with a CD4 count between 50 and 200 cells/JlI had started ART 
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Figure 16: Time to start ARV in the cohort by CD4 categories. 
3.1.2.4 Time to LTF or death from HIV in the cohort (non-ARV patient-time) 
The outcomes LTF and death due to HIV were combined and analyzed using the survival 
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Each one-year increase in age protected against the outcome by 3% (p<0.001) and males 
were at 48% greater risk of LTF or death from HIV than females (p=0.003). 
3.1.3 Section III: Time to TB in the cohort 
The time to TB was analyzed in the cohort, which revealed that 87.8% remain without 
contracting TB in the first year and 78% in the second year (Figure 18). When restricting 
the analysis to those not receiving ART with a first CD4 count <200 cells/).!I, 18% 
contracted TB cumulatively by the first year and 46% by the second year (Figure 19). 
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Figure 19: Time to TB in the cohort restricted to (non-ART) and below 200 CD4 count. 
3.1.4 Section IV: Analysis of ARV group 
One hundred and fourteen (21.3%) of the total cohort started ARV therapy. Time to LTF 
and death due to HIV was analysed to describe the effectiveness of ART within this 
cohort. The analysis describes the duration to outcomes such as HIV related death, and 
certain laboratory outcomes such as CD4 count and viral load. 
The survival estimate of remaining in care (excluding deaths) after starting ART was 
97% ( 95% CI, 83-95%) at 12 months (Figme 20). The product-limit estimate of survival 
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Figure 20: Time to L TF in ARV group. 
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Figure 21: Time to death of HI V among (ARV group) . 
The changes in CD4 count and viral load from the baseline compared with at 6 and 12 
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Durtllion in mon1hs 
Number with CD4 count 47 27 
Median change from baseline 127 163 
Interquartile range (IQR) 68 - 184 132 - 277 
Number with Viral load results 45 26 
Percentage <400 copies/ml 87.1 92.9 













Five hundred and thirty four patients enrolled at the HIV service at site B in 2002 or 45 
patients each month. Women comprise a higher proportion than men. Women also tend 
to be younger in keeping with the epidemiology of HIV in South Africa (Simbayi, 
Shisana, & Human Sciences 2002) . Approximately forty percent of the cohort presented 
with CD4 counts less than 200 cells/!J.1. Those with advanced disease were more likely to 
be referred from other clinical services such as TB and hospitals . Women present with 
higher CD4 counts, which could in part be due to the larger number of women 
undergoing voluntary counselling and testing (VCT) as part of MTCT when they are not 
otherwise ill. The fact that those referred from MTCT have higher CD4 counts confirms 
this. 
The correlation between the CD4 count and HIV clinical stage, (Table 6), was 
comparable to a study done in South Africa (Post & Maartens 2001) before ART was 
available. 
The WHO identifies MTCT and TB as major entry-points for ARV therapy. With TB 
patients comprising 30.9% of the cohort at the time of enrolment, and as they generally 












The lower risk of loss to follow-up for TB patients may relate to better knowledge of HIV 
as a result of attendance at a health facility for 6 to 8 months, or to the relationship 
developed with the health services during that period. It could also be related to the fact 
that TB patients are sicker, and therefore more motivated to remain in care. 
The extremely high rate of loss to fol1ow-up is a major limitation in describing outcomes 
pre-ART initiation. This study attempted to explore, as far as possible, the characteristics 
of patients lost to follow-up, comparing them with the cohort in general. Patients who 
are not eligible for ARVs are less ill, and are less likely to remain in care. The higher 
proportion of those lost to follow-up with very low and very high CD4 counts suggests 
that many of these patients are either not attending as they are clinically well, or that they 
may have died and their vital status is not known to the clinic. 
At the time of the analysis, there was less capacity to provide ART than the demand, and 
the procedures for starting ARVs were more stringent than they are now, resulting in a 
long duration before ART was initiated. The average time from enrolment to starting 
ART was longer than is optimal for patients with very advanced disease such as for those 
with CD4 counts <50 cells/~Ll. It is encouraging nevertheless, that those with the lowest 
CD4 counts were prioritized, and that the majority of those remaining in care and who 
were eligible for ART were eventually started on ART. 
The fact that 78% of the cohort remained free of TB by the second year is limited by the 











However, the results are encouraging in these settings with limited infrastructure. The 
factors that may have contributed to this include the widespread use of co-trimoxazole 
prophylaxis, a nd the fact that patients may have been diagnosed and treated for other 
opportunistic infections (OI's) as suggested by findings of other African studies (Badri et 
al. 1999;Nunn et al. 1992) . 
The very low rate of loss to follow-up after starting ART reflects a selection bias (those 
starting ART demonstrated that they were more likely to remain in care), as well as a 
positive impact of the adherence-promoting interventions. The clinical outcomes for this 
group clearly demonstrate excellent retention and survival, and laboratory outcomes are 
comparable with those described elsewhere for the entire Khayelitsha cohort (Coetzee, 
Hildebrand, Boulle, & et al 2004) 
4.2 Conclusion and recommendations 
The rate of loss to follow-up is higher than expected and severely comprises the ability of 
the programme to report on non-ART outcomes. An examination of sources of referral 
and CD4 counts does however go some way to explaining the loss to follow-up. The 
time to starting ART could have been quicker in this period, but the prioritization was 
overall appropriate. The outcomes for those patients starting ARVs in this clinic are 












• An attempt should be made to reduce loss to follow-up as an outcome in general 
HN care (where ART is not provided or before ART is provided). 
• With high proportions of patients enrolling at services for first time with CD4 cell 
counts below 200 cellS/ill, a faster process to enroll patients on ART needs to be 
developed as soon as possible. 
• As TB clinics are likely to be an important entry points to ART, given the 
nwnbers referred from there and the low CD4 counts of patients referred, every 
attempt should be made to provide VCT at these points and to ensure adequate 
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